Viewing Study NCT01104766


Ignite Creation Date: 2025-12-24 @ 4:32 PM
Ignite Modification Date: 2025-12-28 @ 5:06 PM
Study NCT ID: NCT01104766
Status: COMPLETED
Last Update Posted: 2018-10-29
First Post: 2010-04-09
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Safety and Efficacy of Cariprazine in Patients With Schizophrenia
Sponsor: Forest Laboratories
Organization:

Study Overview

Official Title: A Double-Blind, Placebo and Active-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia
Status: COMPLETED
Status Verified Date: 2018-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: